Where does NuCana plc rank among US patent assignees?

According to USPTO PatentsView (2015–2025 granted utility patents), NuCana plc ranks #11,027 of 49,997 assignees by granted-patent volume, the same sort as the companies listing and top-holders ranking. See /methodology/#corpus-placement.

How many patents does NuCana plc hold?

NuCana plc holds 28 US utility patents granted between 2018 and 2025, spanning 10 technology areas.

What is NuCana plc's Innovation Score?

NuCana plc has an Innovation Score of 42.4 out of 100 (top 31% of the corpus). This composite metric weighs portfolio volume (40%), grant velocity (20%), technology breadth (25%), and claim depth (15%).

What technology areas does NuCana plc focus on?

NuCana plc's top technology area is A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations) with 23 patents, ranking #848 of 6,058 assignees active in that subclass. Grants appear in 10 CPC subclasses total.

Is NuCana plc's patent grant rate increasing or decreasing?

NuCana plc's recent grant velocity is +700% compared to the prior five-year period (grant years, not application filing dates). This indicates accelerating grant output.

What does claim depth mean for NuCana plc's patents?

NuCana plc's patents average 16.0 claims each. This is an aggregate descriptive count from the grant record; it does not establish claim scope, legal strength, enforceability, or design-around risk.

How is the NuCana plc patent data sourced?

All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.

USPTO 2015–2025 USPTO PatentsView Foreign Corporation

NuCana plc

USPTO PatentsView assignee record - 28 granted patents across 10 technology areas, recorded in grant years 2018–2025. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations).

Compiled by PlainPatent · May 15, 2026

RSS updates for this company

Explore the portfolio See the ranking

The verdict

According to USPTO PatentsView, Nucana ranks #11,027 of 49,997 tracked US assignees by granted-patent volume, with 28 patents across 10 technology areas.

#11,027
of 49,997 US assignees by volume: Top 31%
by Innovation Score (42.4/100): 16.0
avg claims per patent: +700%
grant velocity, last 5 yrs

USPTO PatentsView assignee plate

Corpus R11027 · Foreign Corporation #11,027 · 28 grants

GRANTS-SMALL · UPPER-Q · PHOTO-FINISH · CPC-FOCUS · INNOV-PAR · CLAIMS-RICH · TYPE-FRNCORP · VEL-SURGE · BOOK-FULL

GRANTS-SMALL 28 grants
UPPER-Q #11,027/49,997
PHOTO-FINISH Nemoto Kyorindo
CPC-FOCUS A61P · 10 areas
INNOV-PAR 42.4/100
CLAIMS-RICH 16.0 claims/avg
TYPE-FRNCORP Foreign Corp
VEL-SURGE +700% vel
BOOK-FULL 10/10 fields

Nearest grant-volume peer: Nemoto Kyorindo Co., Ltd. (±0 grants)

Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.

How Nucana’s 42.4 Innovation Score adds up

The same four weighted components behind every Innovation Score on PlainPatent: portfolio volume, grant velocity, technology breadth, and claim depth.

Volume 11.6 pts (27%) Velocity 10.0 pts (24%) Breadth 11.2 pts (26%) Claim depth 9.6 pts (23%)

Qualcomm Incorporated · highest

85
NHN Entertainment · near

42
Ninebot (BEIJING) Tech · near

42
NuCana · this assignee

42
The Hillshire Brands · near

42
tooz · near

42
3D Lighting… · lowest

7

What this shows Nucana's Innovation Score is 42.4/100 (top 31% of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.

Does more volume mean deeper claims for Nucana?

Each dot is one of Nucana’s 8 nearest volume peers (same corpus rank neighbourhood as the chart above), placed by total granted patents (horizontal) against average claims per patent (vertical). Nucana’s own 16.0 claims/patent is at or below the 18.4 median for these volume peers. Volume here does not track with deeper claims; several lower-volume peers claim more thoroughly per patent.

Nucana vs its 8 nearest volume peers: granted patents vs average claims per patent. Source: USPTO PatentsView.

Where Nucana's grants concentrate

NuCana plc is a focused PatentsView assignee: 10 CPC subclasses with 82.1% of grants classified under A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations). Peak complete grant year is 2023 (6 grants) versus a trough of 1 in 2019. By volume, Nucana sits between Nemoto Kyorindo Co., Ltd. and Orexo AB.

Nucana's three-year grant acceleration

NuCana plc shows 15 grants in 2022–2024 against only 10 in 2019–2021. That prior window is too thin for a growth multiple (rename and spin-out assignees look artificially high when the baseline is near zero), so PlainPatent withholds a ranked acceleration claim here.

Nemoto Kyorindo

28
Neochord

28
Neuropro

28
Next Silicon

28
O2 Partners

28
Ondal Medical Sys…

28
Opko Biologics

28
Orexo AB

28
Nucana ◀

28

What this shows NuCana holds 28 patents at rank #11,026, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.

Companies ranked near NuCana

By rank, the assignees closest to #11,026 in granted patent volume.

Leaders in A61P (Specific Therapeutic Activity OF Chemical Compounds OR Me…)

Other assignees with the most granted patents in NuCana's primary technology class.

Assignees with similar portfolio profiles

Two PlainPatent-derived peer sets for NuCana, neither rank-band nor same-CPC leaders (those blocks stay above). In A61P (Specific Therapeutic Activity OF Chemical Compounds OR Me…), NuCana ranks #848 of 6,058 assignees by patent count in that subclass.

Similar innovation score

Nearest assignees by Innovation Score (42 here).

The Hillshire Brands Company 42 tooz technologies GmbH 42 Ninebot (BEIJING) Tech Co., Ltd. 42 NHN Entertainment Corporation 42

Nucana's Innovation Score vs. every tracked assignee

Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)

42 Top 31% higher than 69% of 49,997 US assignees

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

USPTO utility patent grants by year · 2018–2025

Grants by year

Teal-shaded recent years (2020–present) versus the 2018–2019 baseline. Full figures in the table below.

View data table

NuCana plc patent grants by year, 2015–2025
Year	Patents Granted	Share of Period
2018	2	7.1%
2019	1	3.6%
2020	5	17.9%
2021	4	14.3%
2022	5	17.9%
2023	6	21.4%
2024	4	14.3%
2025partial year	1	3.6%

Which technologies does NuCana plc patent most?

A61P - Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations 23

C07H - SUGARS; Derivatives THEREOF; NUCLEOSIDES; NUCLEOTIDES; Nucleic Acids 19

A61K - Preparations FOR Medical, Dental OR Toiletry Purposes 15

C07F - Acyclic, Carbocyclic OR Heterocyclic Compounds Containing Elements Other Than Carbon, Hydrogen, Halogen, Oxygen, Nitrogen, Sulfur, Selenium OR Tellurium 5

Y02P - Climate Change Mitigation Technologies IN THE Production OR Processing OF Goods 4

C07B - General Methods OF Organic CHEMISTRY; Apparatus Therefor 3

C07K - Peptides 1

B01J - Chemical OR Physical Processes, e.g. Catalysis OR Colloid CHEMISTRY; Their Relevant Apparatus 1

B82Y - Specific Uses OR Applications OF NANOSTRUCTURES; Measurement OR Analysis OF NANOSTRUCTURES; Manufacture OR Treatment OF Nanostructures 1

H01S - Devices Using THE Process OF Light Amplification BY Stimulated Emission OF Radiation [LASER] TO Amplify OR Generate LIGHT; Devices Using Stimulated Emission OF Electromagnetic Radiation IN Wave Ranges Other Than Optical 1

Top 10 of 10 technology areas

More on this record

Data Source

USPTO PatentsView, US granted patents 2015–2025

View all rankings → How is Innovation Score calculated?

What to do with this data

NuCana plc's patent record in context - here's where to go next.

NuCana plc's lead technology class is A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations), 82.1% of its portfolio - see every assignee active in that class. Explore A61P
Ranked #11,027 of 49,997 tracked assignees by patent volume - see the full leaderboard. See the ranking
Compare NuCana plc against Nemoto Kyorindo Co., Ltd., an assignee filing at a similar volume. Compare portfolios
Innovation Score of 42.4/100 blends volume, velocity, technology breadth, and claim depth. How it's calculated

Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.

Data sourced from USPTO PatentsView - official U.S. government patent data. See our methodology for computation details. Retrieved and formatted by PlainPatent

Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the USPTO PatentsView database. Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

Data sources used on this page

USPTO PatentsView - the disambiguated bulk patent-grant, assignee, and CPC data this page's figures are derived from. patentsview.org
Cooperative Patent Classification (CPC) - the joint USPTO/EPO classification scheme used to group patents by technology area. cooperativepatentclassification.org
USPTO Patent Public Search - the official interface to verify the status of any individual patent. ppubs.uspto.gov

Compiled by PlainPatent, US Patent Intelligence Editorial Process · May 15, 2026

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.